The mid-size pharmaceutical market is expected to grow from US$ 690,105.2 million in 2022 to US$ 1,000,584.3 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.
Revenue, therapy area, R&D expenditure, and reach are among the critical segments of the global pharmaceutical industry. Mid-size pharmaceutical is among the three categories of the pharmaceutical industry. It emphasizes the development of generic drugs and the development of rare disease therapies. The mid-sized pharmaceutical companies have their revenue in the range of US$ 1 billion to US$ 10 billion. The increasing prevalence of chronic diseases, rapidly rising elderly population, and the surging number of products launches and approvals is expected to aid the mid-size pharmaceutical market growth.
The report provides insights and in-depth analysis of the mid-size pharmaceutical market, emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players and the impact of the COVID-19 pandemic on the market across all major regions. The COVID-19 pandemic affected three main aspects of the global economy—manufacturing, supply chain, and financial markets. However, the pandemic impact on the mid-size pharmaceutical market was initially negative, which became positive later. In the beginning of the COVID-19 pandemic, the mid-size pharmaceutical market in the regions faced numerous short-term and long-term challenges, including direct impacts on productions and demands, financial impacts on manufacturing companies, and disruptions in supply chain and markets. In mid-size pharmaceutical markets, the effects of the pandemic were nearly predictable. The result was extremely high demand and funding for products essential to the care and treatment of patients, such as vaccines for infectious diseases, respiratory diseases, diabetes, and influenza. However, budgets for nonessential drugs were limited or unavailable.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Mid-Size Pharmaceutical Market: Strategic Insights
Market Size Value in US$ 690,105.2 Million in 2022 Market Size Value by US$ 1,000,584.3 Million by 2028 Growth rate CAGR of 6.4% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Mid-Size Pharmaceutical Market: Strategic Insights
| Market Size Value in | US$ 690,105.2 Million in 2022 |
| Market Size Value by | US$ 1,000,584.3 Million by 2028 |
| Growth rate | CAGR of 6.4% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Since, the regions have quickly changed trial management, most can deliver the clinical trial services as per clients’ needs. Biotech companies are currently initiating clinical trials in the regions. Since the initial outbreak, the situation in Asia Pacific has improved. As of May 2020, 97% of the sites reopened for patient visits, and 83% of the sites are open for on-site CRA visits. Moreover, hospitals in China are 90% open for inpatient/outpatient visits compared to previous years. Also, clinical sites are returning to normal operations.
Based on region, the mid-size pharmaceutical market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.
Lucrative Regions for Mid-Size Pharmaceutical Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
Increasing Prevalence of Chronic Disorders Drives Mid-Size Pharmaceutical Market
Increasing Prevalence of Chronic Disorders Drives Mid-Size Pharmaceutical Market
The aging population and changing social behavior contribute to the steady increase in common and costly long-term health problems. With the accelerating urbanization, people are adopting a sedentary lifestyle, which boosts the rates of obesity and cases of illnesses, such as diabetes. According to the World Health Organization, the prevalence of chronic diseases is projected to increase by 57% by 2026. Increasing demand for health care systems due to the rising incidence of chronic illnesses has become a major concern. For instance, according to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to increase to 62 million by 2045. The increase in disease prevalence would be about 35% during the predicted period. Pandemics exert periodic and enormous disruptive strains on fitness systems. Healthcare establishments across the world want to be geared up to collectively comprise outbreaks once they occur. Thus, the increasing prevalence of chronic disorders boosts the mid-size pharmaceutical market growth.
Type-Based Insights
Based on type, the mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. It is expected to be one of the fastest-growing segments. The market growth for the segment is attributed to the increasing budget allocation by pharmaceutical companies for drugs marketing and higher disposable income.
Mid-Size Pharmaceutical Market, by Type – 2022 and 2028
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Drug Development Type-Based Insights
Based on drug development type, the mid-size pharmaceutical market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Increasing demand for contract development and manufacturing organizations (CDMOs) and the rising number of new entrants in the market would propel the market growth for the outsource segment during the forecast period.
Formulation-Based Insights
Based on formulation, the mid-size pharmaceutical market is segmented into tablets & capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. The wide usage of tablets and capsules in long-term treatments, easy use of sprays, and innovative injectable formulations, such as prefilled and fixed doses syringes, are anticipated to propel the growth of the market for the tablets & capsules segment during the forecast period.
Therapy Class-Based Insights
Based on therapy class, the mid-size pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Owing to the rising prevalence of chronic diseases and the growing incidence of cancer, the market for the cancer segment is anticipated to grow rapidly during the forecast period.
The mid-size pharmaceutical market players are adopting organic and inorganic strategies, including product launch and expansion, to expand their footprint and product portfolio globally. DAIICHI SANKYO COMPANY, LIMITED; Eisai Co., Ltd.; Regeneron Pharmaceuticals, Inc; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd; Alexion Pharmaceuticals, Inc.; Mallinckrodt; Endo Pharmaceuticals Inc.; Les Laboratories Servier; and UCB S.A. are among the leading companies in the mid-size pharmaceutical market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Drug Development Type, Formulation, and Therapy Class
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
DAIICHI SANKYO COMPANY LIMITED and Regeneron Pharmaceuticals, Inc, are the top two companies that hold huge market shares in the mid-size pharmaceuticals market.
The mid-size pharmaceuticals market majorly consists of players such as DAIICHI SANKYO COMPANY LIMITED, Eisai Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc., Mallinckrodt, Endo Pharmaceuticals Inc., Les Laboratories Servier, UCB S.A. amongst others.
In 2021, the hip outsource held the largest share of the market, by drug development type. It is expected to report a higher CAGR of 6.7% during 2021–2028.
In 2021, the over-the-counter segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. The major driving factors for the growth of the over-the-counter segment are increasing budget allocation by pharmaceutical companies for the marketing of drugs, higher disposable income, and the rising prevalence of chronic diseases. Moreover, the increasing self-medication tendency among the population is one of the significant factors in the growth of the over-the-counter (OTC) segment.
The CAGR value of the mid-size pharmaceuticals market during the forecasted period of 2021–2028 is 6.4%.
Key factors that are driving the growth of this market are the growing prevalence of prevalence of chronic disorders and rising number of product launches and approvals are expected to drive the market during the forecast period.
Mid-size pharmaceutical is among the three categories of pharmaceutical industry. The global pharmaceutical industry is segmented on the basis of their revenue, therapy area, R&D expenditure, reach etc. The mid-sized pharmaceutical companies are those companies which have their revenue in range of US$ 1 billion to US$ 10 billion. Mid-size pharmaceutical emphasizes on generic drug and development of rare disease therapies.
The List of Companies - Mid-Size Pharmaceutical Market
- DAIICHI SANKYO COMPANY LIMITED
- Eisai Co., Ltd.
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
- Alexion Pharmaceuticals, Inc.
- Mallinckrodt
- Endo Pharmaceuticals Inc.
- Les Laboratories Servier
- UCB S.A.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Mid-Size Pharmaceutical Market
Jun 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jun 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jun 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)